CLINICAL STUDY

Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with Graves’ disease

Turan E

Department of Endocrinology and Metabolic Disease, Medical School of Bozok University, Yozgat, Turkey.
drelifturan@hotmail.com

ABSTRACT

AIM: While the ratio of neutrophil-to-lymphocyte (NLR) increases with inflammation, its importance in Graves’ disease is not clear. The aim of this study was to evaluate NLR, a marker of chronic inflammation, in Graves’ disease.

METHODS: 86 Graves’ patients (37 before treatment, 49 euthyroid patients after treatment) and 112 controls were enrolled. Hematologic parameters, thyroid function tests, age and gender were recorded. NLRs were calculated. Firstly, groups were composed as Graves’ group (Group 1) and participants without thyroid disorder as control group (Group 2). Secondly, Graves’ patients before treatment were considered as Group 1a, euthyroid Graves’ patients after antithyroid treatment were considered as Group 1b. These groups were compared with each other in terms of descriptive data and hematological parameters.

RESULTS: Lymphocyte, monocyte, platelet, free T3, and free T4 levels were significantly higher in Graves’ group than the controls. TSH and NLR were significantly lower in Graves’ group than the controls. Differences among group 1a and group 1b for monocyte (p = 0.013), for basophil (p = 0.002), for platelet (p = 0.029), and for NLR (p = 0.029) were statistically significant.

CONCLUSION: Unlike other inflammatory diseases, in Graves’ disease; hematological parameters may not give information about inflammatory state of the disease. Therefore, NLR should be evaluated with other serum inflammatory markers in Graves’ disease (Tab. 2, Fig. 1, Ref. 26). Text in PDF www.elis.sk.

KEY WORDS: Graves’ disease, inflammation, neutrophils, platelet count.

Introduction

Graves’ disease is one of the autoimmune thyroid disorders and the most common reason of thyrotoxicosis. Thyrotoxicosis due to Graves’ disease causes many changes in the whole body. Hemopoietic system is one of the altered systems. Blood cell levels can be affected by thyrotoxicosis (1). Besides thyrotoxicosis, antithyroid drugs may cause side effects in the hematological system (2–4).

Recently, neutrophil-to-lymphocyte ratio (NLR) as simple, non-invasive and cost-effective marker of inflammation, is frequently investigated in inflammatory diseases (5, 6) and malignancies (7).

The aim of this study was to evaluate NLR, a marker of chronic inflammation, and hematological parameters in Graves’ disease.

Material and method

In this study, over 18 years old, 86 (37 before treatment, 49 euthyroid patients after treatment) participants with Graves’ disease and age-sex matched 112 participants without thyroid dis-
of free T3, free T4, TSH, anti-Tg, and anti-TPO were performed on DxI 800 Access Immunoassay (Beckman Coulter Inc., Brea, CA, USA) using a direct chemiluminescence detection system. TSH receptor antibody performed by electrochemiluminescence methods, using the system Cobas e801, Roche® Tc99m thyroid scintigraphy was performed with gamma camera interfaced dedicated computer system (Siemens E.CAM, Siemens Medical Systems Inc., Hoffman Estates, IL, USA). Thyroid ultrasonography was performed with an ultrasonography device (LOGIQ P6; GE Healthcare, Milwaukee, USA) equipped with a 10 MHz linear probe. Hematological tests were measured using automated standard laboratory methods. Euthyroidism was defined as the levels of TSH, FT3 and FT4 in normal range. Methimazole was preferred as the first-line treatment for Graves’ disease (8). Propylthiouracil was reserved for patients with side effects. Participants were categorized in two ways. Firstly; patients with Graves’ disease were considered as Group 1, and the control subjects without thyroid disorder were considered as Group 2. These two groups were compared in terms of age, gender, leucocyte, neutrophil lymphocyte, monocyte, eosinophil, basophil, hemoglobin (hb), Free T3, Free T4, TSH levels, NLR, platelet to lymphocyte ratio (PLR). Secondly; patients with Graves’ disease and overt hyperthyroidism, before treatment were considered as group 1a, euthyroid Graves’ patients after 6 months of antithyroid treatment were considered as group 1b. These groups were compared among themselves. Exclusion criteria were; pregnancy, infection, rheumatologic and hematologic disorders. The study was approved by the Bozok University ethics committee (Project no: 2017-KAEEK-189_2018.06.06_02). All procedures were in accordance with the ethical standards of the responsible committee on human studies (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

All statistical analyses were calculated with the Statistical Package for the Social Sciences, version 18.0 (SPSS Inc., Chicago, IL, USA). P value < 0.05 was considered as statistically significant. Baseline characteristics were expressed in numbers and percentage. Continuous variables were expressed as mean ± standard deviation. To compare the two groups; χ²-test was used for categorical variables, student t-test was used for continuous variables with a normal distribution, and Mann-Whitney U-test for the others. In analysis of the three groups; One-way analysis of variance test was used to compare groups. Parameters with non-normal distribution were evaluated by using Kruskal Wallis.

Results

The characteristics of the participants for the two groups are shown in Table 1. In two groups analysis (Group 1 and 2); lymphocyte (p = 0.047), monocyte (p = 0.03), platelet (p = 0.039), free T3 (p < 0.001), and free T4 (p < 0.001) levels were significantly higher in Graves’ disease group than in the control group. TSH (p < 0.001) and NLR (p = 0.019) were significantly lower in Graves’ group than the control group. PLR was similar among the groups (p > 0.05).

Group 1a and Group 1b analysis demonstrated significant difference between groups in terms of monocyte (p = 0.013), basophil (p = 0.002), platelet (p = 0.029) levels, NLR (p = 0.029), free T4 (p < 0.001), free T3 (p < 0.001) and TSH levels (p < 0.001). Other parameters were similar between the groups (Tab. 2).

Discussion

This study showed that, incompatible with previous data on other autoimmune and inflammatory diseases, NLR was lower in Graves’ disease with overt hyperthyroidism and after Graves’ treatment a significant increase was observed.

Autoimmune diseases can be defined as disorders in which body’s cells inexplicably attack its own tissues. Autoimmunity has the key role in Graves’ disease pathogenesis. Due to the breach of immune tolerance, leucocytes and monocytes migrate to the thy-
lymphocyte counts were significantly lower in the Graves group and we can conclude that these results may probably be the result of increase in lymphocytes in Graves disease.

We found that monocyte and basophil counts were significantly higher in untreated Graves’ patients than in euthyroid Graves’ patients after anti-thyroid treatment and in the controls. Irvine et al. found that the monocyte count in Graves’ patients was similar with the control group (3). There is not enough data about the basophil counts in Graves’ disease.

Cases of thrombocytopenia due to hyperthyroidism have been reported in the literature (25). Although the mechanism is not clearly understood, the possible mechanism has been reported to be the immune-induced thrombocytopenia or hypersplenism in Graves’ disease (26). On the other hand, in Graves’ disease, megakaryocytes increase in bone marrow, while platelet count is normal, and platelet survival time is shortened (26). In our study, platelet counts were significantly increased in the Graves’ group with overt hyperthyroidism compared to the controls and euthyroid Graves’ patients.

There are some limitations of our study; firstly it was a retrospective study and we do not have an inflammation marker to compare our results, such as sedimentation, C-reactive protein, tumor necrosis factor, interleukin 1 β, interleukin 6. Secondly, we had a small number of patients in the groups. Thus, further large-scale studies are needed to prospectively evaluate these hematologic markers in Graves’ disease.

Conclusion

Our results showed that NLR was decreased and platelet count was increased in untreated Graves’ patients and these results were different from the literature. Significantly lower NLR in Graves’ disease is thought to be compatible with the pathophysiology of the disease and antithyroid drug’s suppressive effect on lymphocytes. NLR should be evaluated using other serum inflammatory markers in Graves’ disease and larger prospective studies are needed to fully assess the benefits of NLR in patients with Graves’.

References

1. Melmed S SPK, Larsen P.R, Kronenberg HM. Williams Textbook of Endocrinology. United States of AMerica: Saunders Elsevier; 2011.
2. Cooper DS. Antithyroid drugs. New Engl J Med 2005; 352 (9): 905–917.
3. Irvine W, Wu F, Urbaniak S, Toolis F. Peripheral blood leucocytes in thyrotoxicosis (Graves’ disease) as studied by conventional light microscopy. Clin Exp Immunol 1977; 27 (2): 216.
4. Sprikkelman A, Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 1994; 8 (12): 2031–2036.
5. Chittawar S, Dutta D, Qureshi Z, Surana V, Khandare S, Dubey TN. Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in Indians with type-2 diabetes. Indian J Endocrinol Metab 2017; 21 (6): 864.
6. Kucuk A, Uslu AU, Ugan Y, Bagceci S, Karahan AY, Akarmut A et al. Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis. Bratisl Med J 2015; 116 (12): 722–725.
7. Ramos-Esquivel A, Rodriguez-Porras I, Porras J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. Breast Dis 2017; 37 (1): 1–6.
8. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J 2018; 7 (4): 1–20.
9. Li N. Platelet-lymphocyte cross-talk. J Leukocyt Biol 2008; 83 (5): 1069–1078.
10. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Med J 2001; 102 (1): 5–14.
11. Eakin DL, Peake RL, Weiss GB. Effect of therapy on the neutropenia of hyperthyroidism. Southern Med J 1983; 76 (3): 335–337.
12. Talansky AL, Schulman P, Vinciguerra VP, Margouleff D, Budman DR, Degnan TJ. Pancytopenia complicating Graves’ disease and drug-induced hypothyroidism. Arch Intern Med 1981; 141 (4): 544–545.
13. Kinjo Y. A case of Graves’ disease with myelodysplastic syndrome, in which Mercazole improved pancytopenia. Clin Endocrinol 2000; 48: 60–63.
14. Van der Weerd K, Van Hagen P, Schrijver B, Kwekkeboom DJ, De Herder W, Ten Broek M et al. The peripheral blood compartment in patients with Graves’ disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes. Clin Exp Immunol 2013; 174 (2): 256–264.
15. Süreli TMÇU, Kullanmına P, Nötopeni B. Neutropenia Due to Very Long Time Propylthiouracil Usage in Toxic Multinodular Goiter. 2016.
16. Peng Y, Qi Y, Huang F, Chen X, Zhou Y, Ye J et al. Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave’s disease. Oncotarget 2016; 7 (48): 78680–78687.
17. Klatka M, Grywalska E, Surdecka A, Tarach J, Klatka J, Rolinski J. Peripheral blood lymphocyte apoptosis and its relationship with thyroid function tests in adolescents with hyperthyroidism due to Graves’ disease. Arch Med Sci 2012; 8 (5): 865–873.
18. Wenisch C, Myskiv D, Gessl A, Graninger W. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab 1995; 80 (7): 2122–2126.
19. Faria SS, Fernandes Jr PC, Silva MJ, Fontes W, Freitas-Junior R et al. The neutrophil-to-lymphocyte ratio: a narrative review. E cmannercmedscience 2016; 10.
20. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88 (1): 218–230.
21. Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acartürk G et al. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. Diabet Technol Ther 2013; 15 (11): 942–947.
22. Bilge M, Yesilova A, Andis, M, Helvacı A. Neutrophil- and Platelet-to Lymphocyte Ratio in Patients with Euthyroid Hashimoto’s Thyroiditis. Exp Clin Endocrinol Diabet 2018; 126.
23. Ciray H, Aksoy AH, Ulu N, Cizmecioglu A, Gaipov A, Solak Y. Nephropathy, but not Angiographically Proven Retinopathy, is Associated with Neutrophil to Lymphocyte Ratio in Patients with Type 2 Diabetes. Exp Clin Endocrinol Diabet 2015; 123 (5): 267–271.
24. Aktas G, Sit M, Dikbas O, Erkol H, Altinordu R, Erkus E et al. Elevated neutrophil-to-lymphocyte ratio in the diagnosis of Hashimoto’s thyroiditis. Revista da Associaiao Med Brasil 2017; 63 (12): 1065–1068.
25. Adrouny A, Sandler RM, Carmel R. Variable presentation of thrombocytopenia in Graves’ disease. Arch Intern Med 1982; 142 (8): 1460–1464.
26. Panzer S, Haubenstock A, Minar E. Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. J Clin Endocrinol Metab 1990; 70 (2): 491–496.

Received March 11, 2019.
Accepted April 29, 2019.